10-K/A: Bio Green Med Solution Shifts Strategy Amid Going Concern Doubt

Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, is undergoing significant restructuring, including a strategic focus on its plogo clinical program and a UK subsidiary liquidation, while facing substantial doubt about its ability to continue as a going concern.

Summary

• The company, formerly Cyclacel Pharmaceuticals, Inc., changed its name to Bio Green Med Solution Inc. on September 12, 2025, and this amendment is filed under the new name, though internal references remain as Cyclacel Pharmaceuticals, Inc.
• A re-audit of 2024 and 2023 financial periods was conducted by a new independent registered public accounting firm to achieve efficiencies and future cost savings.
• The company effected a 1-for-15 reverse stock split on December 18, 2023, and stockholders approved another reverse stock split at a ratio of 1:4 to 1:16, expected in May 2025.
• Management is exploring strategic alternatives to preserve cash, including a potential transaction with investor David Lazar.
• The company is liquidating its wholly-owned United Kingdom subsidiary, Cyclacel Limited, which was announced on January 31, 2025.
• The strategic focus has narrowed to only the plogo clinical program, with fadraciclib being marketed for sale by the joint liquidator of the UK subsidiary.
• The deconsolidation of the UK subsidiary is anticipated to increase stockholders' equity by approximately $5.0 million and will be reported in the Q1 2025 Form 10-Q.
• The company reported a net loss of $11.2 million for the year ended December 31, 2024, a significant improvement from $22.5 million in 2023.
• Cash and cash equivalents stood at $3.1 million as of December 31, 2024, down from $3.4 million in 2023.
• The company has incurred operating losses since its inception in 1996, with an accumulated deficit of $439.5 million as of December 31, 2024.
• The Board of Directors suspended payment of the quarterly cash dividend on the 6% Convertible Exchangeable Preferred Stock scheduled for February 1, 2025, and for previous quarters in 2024.
• Multiple capital raises occurred in late 2023 and 2024, including the issuance of common stock, pre-funded warrants, and Series A, B, C, D, and E convertible preferred stock, generating several million dollars in gross proceeds.
• The company's corporate headquarters moved from Berkeley Heights, New Jersey, to Kuala Lumpur, Malaysia, effective March 1, 2025.

Sentiment

Score: 2

Explanation: The company faces substantial doubt about its ability to continue as a going concern, has a history of significant losses, and relies heavily on dilutive capital raises. While cost reductions and a strategic focus are positive steps, the overall financial health and future viability remain highly precarious.

Positives

• Net loss decreased significantly to $11.2 million in 2024 from $22.5 million in 2023, representing a 50.2% reduction.
• Research and development expenses decreased by $12.5 million (65%) from $19.2 million in 2023 to $6.7 million in 2024, primarily due to cost reduction efforts and program focus.
• General and administrative expenses decreased by $1.3 million (20%) from $6.7 million in 2023 to $5.4 million in 2024.
• Net cash used in operating activities decreased by $8.1 million, from $16.1 million in 2023 to $8.0 million in 2024.
• The company successfully raised $7.8 million in net cash from financing activities in 2024 through stock and warrant issuances.
• Regained compliance with Nasdaq's equity requirement as of February 25, 2025.
• The deconsolidation of the UK subsidiary is anticipated to increase stockholders' equity by approximately $5.0 million.
• Plogo, the company's sole remaining clinical program, has shown stable disease in pretreated patients with gastrointestinal, lung, and ovarian cancers in Phase 1/2 studies.

Negatives

• The company has a history of operating losses since 1996 and an accumulated deficit of $439.5 million as of December 31, 2024.
• There is substantial doubt regarding the company's ability to continue as a going concern beyond the second quarter of 2025, based on current cash balances and operating plan.
• The company does not currently have sufficient funds to complete development and commercialization of any of its drug candidates.
• The Board of Directors suspended payment of quarterly cash dividends on the 6% Convertible Exchangeable Preferred Stock for February 1, 2025, and for previous quarters in 2024, indicating cash constraints.
• Revenue from clinical trial supply decreased by 90% from $420,000 in 2023 to $43,000 in 2024, and no revenue is expected for the foreseeable future.
• Foreign exchange losses increased to $54,000 in 2024 from $414,000 in 2023 (though the difference is a positive change in loss, it's still a loss). Unrealized foreign exchange movements related to intercompany loans resulted in a loss of $2.9 million in 2024.
• Interest income decreased by 95% to $12,000 in 2024 from $266,000 in 2023 due to lower cash balances.
• Income tax benefit decreased significantly by $2.2 million (74%) due to ineligibility to recover qualifying R&D expenditure incurred in 2024.
• Working capital deficit increased from $(717,000) in 2023 to $(2,594,000) in 2024.
• The company's stock is considered a highly speculative investment due to its history of losses and uncertainty about future profitability.

Risks

• Clinical trials are expensive, time-consuming, subject to delay, and may require funding beyond available capital.
• Significant delays, setbacks, negative results, or termination of clinical trials may occur.
• Reliance on scientifically unvalidated biomarkers may lead to inefficient resource allocation.
• Inability to directly control the timing, conduct, and expense of clinical trials due to reliance on third-party CROs and other parties.
• Lack of in-house manufacturing capacity and reliance on third-party manufacturers for clinical and commercial supplies.
• Difficulties in managing growth and expanding operations from discovery/development to commercialization.
• Drug candidates are subject to extensive, costly, and time-consuming regulation, with no guarantee of commercial approval.
• Even if clinical trials are successful, product candidates may fail for other reasons (e.g., market acceptance, manufacturing difficulties, adverse side effects).
• Intense competition from other companies developing less expensive, safer, or more effective drugs.
• Failure to enter into and maintain successful strategic alliances may reduce or delay drug candidate development or increase expenditures.
• Failure of drug candidates or distribution partners' products to achieve market acceptance could prevent significant revenue generation.
• Business may be affected by government and third-party payors' efforts to contain or reduce healthcare costs.
• Potential product liability exposure could lead to substantial liability and limit commercialization.
• Subject to numerous and varying privacy and security laws, with non-compliance resulting in penalties and reputational damage.
• Substantial doubt regarding the ability to continue as a going concern, requiring additional capital that may not be available on reasonable terms.
• Unstable market and economic conditions may adversely affect business, financial condition, and stock price.
• Failure to comply with Nasdaq Capital Market listing requirements could lead to delisting.
• Funding constraints may negatively impact R&D activities, delaying plogo development and commercialization.
• Tight and competitive labor market, increasing employee turnover and compensation costs, harming ability to attract and retain skilled personnel.
• Failure to adequately enforce or defend intellectual property rights could harm the business.
• Substantial costs may be incurred from litigation or other proceedings related to patent and intellectual property rights.
• Failure to achieve and maintain internal controls in accordance with Sarbanes-Oxley Act could materially adversely affect business and stock price.
• Increased costs and management resources as a public company, with potential failure to comply with public company obligations.
• Limited ability to pay cash dividends on preferred stock, with no assurance of future quarterly dividends.
• Future sale of common and convertible preferred stock and future issuances upon conversion could negatively affect stock price and cause dilution.
• Significant number of registered shares (including warrants) relative to outstanding common stock could cause downward pressure on market price.
• Management team will have broad discretion over the use of net proceeds from any securities sales.
• Applications for regulatory approval could be delayed or denied due to problems with studies conducted before licensing rights to product candidates.
• Ongoing regulatory requirements even after obtaining marketing approval.
• Undesirable side effects from product candidates could delay/prevent marketing approval, limit commercial potential, or result in negative consequences post-approval.
• Product development may not uncover all possible adverse events.
• Difficulties in managing growth and expanding operations as the company evolves towards commercialization.
• Inadequate funding for regulatory agencies (FDA, SEC) could hinder their ability to perform normal business functions, negatively impacting the business.
• Employees, contractors, etc., may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Inability to compete successfully in the marketplace due to existing or new competitor products.
• Early stage of development with no products generating significant revenues.
• Insurance policies are expensive and may not protect against all business risks, leading to significant uninsured liabilities.
• Reliance on third-party supply and manufacturing partners for drug supplies, with risks of limitations, interruptions, or quality issues.
• Claims for indemnification by directors and officers may reduce available funds.
• Exposure to risks related to foreign currency exchange rates.
• Security incidents, loss of data, and other disruptions could compromise sensitive information and expose to liability.

Future Outlook

The company anticipates that overall research and development expenses for the year ended December 31, 2025, will decrease significantly as it focuses solely on the plogo clinical program, with no further expenditure related to fadraciclib. General and administrative expenditures are also expected to reduce significantly following the deconsolidation of the UK Subsidiary. The company does not expect to report revenue for the foreseeable future and does not expect to be eligible for UK research and development tax credits for 2025. Future funding requirements will depend on the progress and cost of clinical trials, regulatory approvals, manufacturing, and commercialization efforts. The company plans to finance future cash needs through public or private equity offerings, debt financings, or strategic collaborations, but there is no guarantee of securing additional funding on acceptable terms.

Management Comments

• Management is exploring and reviewing strategic alternatives on an expedited basis to preserve cash, including a potential transaction with investor David Lazar.
• The Board directed management to reduce operating costs, which included the liquidation of the company's wholly owned United Kingdom subsidiary.
• The company has determined to focus on the development of the plogo clinical program only as part of its efforts to reduce operating costs.
• The deconsolidation of the UK subsidiary is anticipated to increase stockholders' equity by approximately $5.0 million.
• We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient's overall survival.
• Our strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.
• We currently retain all global marketing rights to the compounds associated with our clinical-stage drug program.
• We believe that we are well placed to exploit the significant opportunities that this area offers for new drug discovery and development.
• We intend to enter into selected partnering arrangements and to retain co-promotion rights as appropriate, generally planning to develop compounds through the Phase 2 proof-of-efficacy stage before seeking a partner.
• We believe that our marketable securities investments are safe and highly liquid, but we cannot guarantee that our investment portfolio will not be negatively impacted by recent or future market volatility or credit restrictions.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, intense competition, and extensive regulatory hurdles. The company's strategic shift to focus on a single clinical program (plogo) and divest another (fadraciclib) is a common response to funding constraints and the need to prioritize assets in a capital-intensive sector. The ongoing efforts to raise capital through various equity instruments reflect the typical financing challenges faced by clinical-stage biopharmaceutical companies that have not yet achieved profitability. The mention of biomarker use, while not yet fully validated by regulatory bodies, aligns with broader industry trends towards precision medicine and targeted therapies. The company's move to a new headquarters in Malaysia could indicate a shift in operational strategy or cost-saving measures, potentially leveraging different talent pools or regulatory environments.

Comparison to Industry Standards

• The company's history of operating losses since 1996 and accumulated deficit of $439.5 million are typical for early-stage biopharmaceutical companies, which often require significant investment over many years before commercializing products and achieving profitability.
• The 'going concern' warning is a serious indicator, common among smaller biotechs with limited cash runways, but it signals a higher risk profile compared to more established, revenue-generating pharmaceutical companies like Pfizer or Merck.
• The reliance on third-party CROs and CMOs for clinical trials and manufacturing is standard practice in the industry, especially for companies without extensive in-house infrastructure.
• The use of reverse stock splits to maintain Nasdaq listing compliance is a common tactic for companies whose stock price has fallen significantly, but it often signals underlying financial distress and can be viewed negatively by investors.
• The competitive landscape, with companies like Cardiff Oncology, Arbutus, Boehringer Ingelheim, GlaxoSmithKline, Merck, Onconova, and Takeda evaluating PLK inhibitors, indicates that the plogo program operates in a crowded and highly competitive therapeutic area, making market penetration challenging even if approved.
• The significant dilution from multiple equity and warrant issuances is typical for companies in this stage of development, but it contrasts with mature companies that fund growth through retained earnings or less dilutive debt.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2024, the company was not a party to any material legal proceedings.
• The company may be involved in routine litigation incidental to the conduct of its business from time to time.

Related Party Transactions

• On January 2, 2025, the company entered into a securities purchase agreement with investor David Lazar (who later became interim CEO) to purchase Series C and D Convertible Preferred Stock for $3.1 million.
• On February 4, 2025, the company entered into another securities purchase agreement with David Lazar for a private placement of up to $8,000,000 of common stock.
• On February 11, 2025, David E. Lazar (interim CEO and Secretary) entered into a securities purchase agreement with Datuk Dr. Doris Wong Sing Ee (who later became CEO) to sell 1,000,000 shares of Series C Convertible Preferred Stock and 1,745,262 shares of Series D Convertible Preferred Stock.
• On December 21, 2023, in a separate concurrent insider private placement, the company sold common stock and warrants to Spiro Rombotis (then CEO) and Paul McBarron (then EVP-Finance, CFO, COO) on the same terms as the institutional investors.

Stakeholder Impact

• **Shareholders:** Existing common shareholders face significant dilution from ongoing and future equity issuances, including preferred stock conversions and warrant exercises. The 'going concern' warning poses a substantial risk to the value of their investment. The suspension of preferred stock dividends negatively impacts preferred shareholders.
• **Employees:** The company is experiencing an increasingly tight and competitive labor market with higher turnover rates and increased compensation costs, potentially impacting employee morale and retention. The strategic focus on plogo only and liquidation of the UK subsidiary may lead to job reductions or shifts in roles.
• **Customers/Patients:** The strategic focus on the plogo clinical program aims to provide innovative cancer medicines, potentially benefiting patients if successful. However, delays in clinical trials or failure to obtain regulatory approval would negatively impact patient access to potential new therapies.
• **Suppliers/Creditors:** The company's financial instability and 'going concern' doubt could raise concerns among suppliers and creditors regarding timely payments and future business relationships. The proceeds from recent capital raises are intended to settle outstanding liabilities.
• **Management/Directors:** Recent management and board changes, including resignations and new appointments, indicate a significant shift in leadership. Settlement agreements with resigning officers and directors include payments and indemnification, impacting company resources.

Next Steps

• Continue efforts to raise additional capital through public or private equity offerings, debt financings, or strategic collaborations.
• Focus exclusively on the development of the plogo clinical program.
• Complete the liquidation of the UK subsidiary, Cyclacel Limited, and deconsolidate its financial results in the Q1 2025 Form 10-Q.
• Implement the approved 2025 Reverse Stock Split, expected in May 2025.
• Continue to evaluate in-licensing and acquisition opportunities for new drugs or drug targets.
• Monitor and comply with evolving data privacy and security laws, including GDPR and state-level regulations.

Key Dates

Recommendation

The company explicitly states 'substantial doubt regarding our ability to continue as a going concern' beyond Q2 2025, which is a critical red flag for any investor. Despite a reduction in net loss, the company remains deeply unprofitable with a significant accumulated deficit and minimal cash reserves. The ongoing reliance on highly dilutive capital raises, including multiple preferred stock and warrant issuances, will continue to erode shareholder value. The strategic shift to a single clinical program (plogo) is a high-risk, high-reward gamble, and the liquidation of the UK subsidiary, while a cost-saving measure, indicates a contraction of operations. The suspension of preferred stock dividends further underscores severe cash constraints. Given the extreme financial instability, high operational risks, and continuous dilution, the stock presents an exceptionally poor investment opportunity.

Keywords

Biopharmaceutical, Oncology, Cancer Medicines, Plogosertib, PLK1 Inhibitor, Clinical Trials, SEC Filing, 10-K/A, Corporate Restructuring, Going Concern, Capital Raise, Preferred Stock, Warrants, Reverse Stock Split, Corporate Governance, Risk Factors, Drug Development, Nasdaq Capital Market, Shareholder Dilution, Financial Performance